MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease_Hepatitis
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR)
Organization & Developments: Eiger
Parents
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR)
Children
*Biopharmaceutical company focused on developing therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases
*Eiger BioPharmaceuticals is a privately held biotechnology company developing a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy.
*Exendin 9-39. Exendin, the company's second most developed candidate, is being examined in the treatment of post-bariatric hypoglycemia (PBH).
*Lambda Interferon. Lambda is a first in class type III interferon (IFN) that Eiger in-licensed from Bristol-Myers Squibb (NYSE:BMY) in April 2016, also being evaluated for the treatment of HDV infection.
*Lonafarnib (LNF). This oral therapy in-licensed from Merck (NYSE:MRK) is being investigated for the treatment of HDV, the most severe form of hepatitis.
*Ubenimex for PAH. Ubenimex is an oral therapy for the treatment of Pulmonary Arterial Hypertension (PAH).
2017: Eiger Biopharmaceuticals: Can This $10 Biotech Stock Continue To Rally? - Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
2018: Eiger BioPharmaceuticals: Buy The Dip_seekingalpha.com
2018: What Now For Eiger BioPharmaceuticals? - Bret Jensen
2019: Biotech Analysis Central Preview Series: Eiger Biopharmaceuticals_seekingalpha.com
2019: Eiger Receives Bevy Of Regulatory Support To Guide, Protect, And Accelerate HDV And Progeria Programs_seekingalpha.com
2020: Eiger BioPharmaceuticals: Promising COVID-19 Effort With Peginterferon Lambda Just Entering Clinical Trials
2020: Eiger Looks Like A Solid Long-Term Play After Zokinvy's Approval
2020: Eiger: Upcoming Catalysts And Platform Make It A Buy
2021: Eiger Pharma: Next Up Is HDV
2021: Evaluating An Investment In Eiger BioPharmaceuticals
2022: Eiger BioPharmaceuticals: A Compelling High Beta Story_ seekingalpha.com
2024: Eiger reportedly files for Chapter 11, stock plunges 52%
Jumps
*Key People: Eiger
Finance & Acquisitions: Eiger